The FDA says that Wegovy and Ozempic deficiency are decided; Hims & her

In a pharmacy, boxes with Ozempic and Wegovy from Novo Nordisk can be seen.

Hollie Adams | Reuters

The long -time lack of us Novo Nordisk'S Blockbuster Weight Loss Injection Wegovy and Diabetes Treatment Ozempic will be solved after more than two years, said the US Food and Drug Administration on Friday.

The decision of the FDA will threaten the ability to improve pharmacies in order to make far cheaper versions of the interior versions of the interior versions in the next few months. Many patients were based on non -approved versions of wide houses and Ozempic, since the compounding pharmacies are allowed to produce versions of branded medication in short supply.

Novo Nordisk's share closed about 5% higher on Friday. Meanwhile shares of Hims & HeinA telemedicine company that offered merged Wegovy and Ozempic fell by more than 25%.

The active ingredient in the injectable medication of Novo Nordisk, Semaglutid, has been lacking in the USA since 2022 after demand has been raised. Novo Nordisk and his rivals have forced this Eli Lilly In order to invest their respective weight loss and diabetes drugs intensively in order to expand their manufacturing footprints -it can pay off.

The FDA found that Novo Nordisk's offer and manufacturing capacity for semaglutidinjection can now meet the current and forecast demand in the United States. Chain to pharmacies.

“We are pleased that the FDA has declared that the supply of the only real Semaglutid medication approved by the FDA has been solved,” said Dave Moore, Executive Vice President of the US Operations and Global Business Development.

He added that “nobody affects their health due to misinformations and has to grab fake or illegitimate knockout medication that represent the patient considerable security risks.”

The FDA announced the FDA only a few months after the agency explained the lack of Tirzatide – the active ingredient in Eli Lilly's weight loss -injection zepbound and diabetes – opposite Mounjaro – was over.

The decision of the FDA on Friday could position Novo Nordisk better to compete with Eli Lilly on the booming market for weight loss, which could be worth more than $ 150 billion a year after 2030 analysts.

Threat for increased medication

The decision of the agency, which is based on a comprehensive analysis, essentially marks the end of a period in which composite pharmacies cannot create, distribute, distribute or issue versions of Semaglutide, without being contrary to violations of the lack of treatment in connection with violations place.

Compounding pharmacies will have to stop increased versions of Semaglutid in the next 60 to 90 days in the next 60 to 90 days, depending on the type of facility, said the agency. This transition period will probably give the patient time to switch to the brand versions of the medication.

In accordance with the FDA rules, however, connections can still produce alternative versions of the medicines if they modify doses, add other ingredients or change the method for treating treatments to meet the needs of a certain patient.

Some patients rely on compound versions because they have no insurance cover for the medication from Novo Nordisk and cannot afford their strong price tags of around $ 1,000 per month. While Ozempic is covered by most health plans, weight loss drugs such as Wegovy are currently not covered by Medicare and another insurance.

Do not miss these findings from CNBC Pro